Cargando…

Targeting MK2 Is a Novel Approach to Interfere in Multiple Myeloma

MAPKAPK2 (MK2), the direct substrate of p38 MAPK, has been well-acknowledged as an attractive drug target for cancer therapy. However, few studies have assessed the functions of it in multiple myeloma (MM). In the present study, MK2 expression of MM patients was analyzed by gene expression profiling...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Mengjie, Sun, Dongdong, Fan, Zhimin, Yuan, Yuxia, Shao, Miaomiao, Hou, Jianhao, Zhu, Yuqi, Wei, Rongfang, Zhu, Yan, Qian, Jinjun, Li, Fei, Yang, Ye, Gu, Chunyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6694709/ https://www.ncbi.nlm.nih.gov/pubmed/31440466 http://dx.doi.org/10.3389/fonc.2019.00722

Ejemplares similares

Dihydroartemisinin Induces Growth Arrest and Overcomes Dexamethasone Resistance in Multiple Myeloma
por: Chen, Ying, et al.
Publicado: (2020)

Corrigendum: Dihydroartemisinin Induces Growth Arrest and Overcomes Dexamethasone Resistance in Multiple Myeloma
por: Chen, Ying, et al.
Publicado: (2021)

Steroid 5α-Reductase Type I Induces Cell Viability and Migration via Nuclear Factor-κB/Vascular Endothelial Growth Factor Signaling Pathway in Colorectal Cancer
por: Wei, Rongfang, et al.
Publicado: (2020)

Acupuncture Synergized With Bortezomib Improves Survival of Multiple Myeloma Mice via Decreasing Metabolic Ornithine
por: Ke, Mengying, et al.
Publicado: (2021)

Suppression of steroid 5α-reductase type I promotes cellular apoptosis and autophagy via PI3K/Akt/mTOR pathway in multiple myeloma
por: Dou, Renjie, et al.
Publicado: (2021)

MK2 is a therapeutic target for high-risk multiple myeloma
por: Gu, Chunyan, et al.
Publicado: (2018)

Bioactive Compounds from Abelmoschus manihot L. Alleviate the Progression of Multiple Myeloma in Mouse Model and Improve Bone Marrow Microenvironment
por: Hou, Jianhao, et al.
Publicado: (2020)

DAZAP1 facilitates the alternative splicing of KITLG to promote multiple myeloma cell proliferation via ERK signaling pathway
por: Zhou, Yanyan, et al.
Publicado: (2022)

AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma
por: Gu, Chunyan, et al.
Publicado: (2022)

Correction: AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma
por: Gu, Chunyan, et al.
Publicado: (2023)

NAT10 promotes cell proliferation by acetylating CEP170 mRNA to enhance translation efficiency in multiple myeloma
por: Wei, Rongfang, et al.
Publicado: (2022)

AIMP1 promotes multiple myeloma malignancy through interacting with ANP32A to mediate histone H3 acetylation
por: Wei, Rongfang, et al.
Publicado: (2022)

NAT10 acetylates BCL-XL mRNA to promote the proliferation of multiple myeloma cells through PI3K-AKT pathway
por: Zhang, Yuanjiao, et al.
Publicado: (2022)

Targeting RFWD2 as an Effective Strategy to Inhibit Cellular Proliferation and Overcome Drug Resistance to Proteasome Inhibitor in Multiple Myeloma
por: Guo, Mengjie, et al.
Publicado: (2021)

BUB1B and circBUB1B_544aa aggravate multiple myeloma malignancy through evoking chromosomal instability
por: Tang, Xiaozhu, et al.
Publicado: (2021)

Current Role of Radiation Therapy for Multiple Myeloma
por: Talamo, Giampaolo, et al.
Publicado: (2015)

In vitro and in vivo efficacy of the novel oral proteasome inhibitor NNU546 in multiple myeloma
por: Zhou, Hui, et al.
Publicado: (2020)

Clinical Value of ctDNA in Hematological Malignancies (Lymphomas, Multiple Myeloma, Myelodysplastic Syndrome, and Leukemia): A Meta-Analysis
por: Tan, Xiangyu, et al.
Publicado: (2021)

Therapeutic Advancements in Multiple Myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2014)

Review on circular RNAs and new insights into their roles in cancer
por: Tang, Xiaozhu, et al.
Publicado: (2021)

Elevated SFXN2 limits mitochondrial autophagy and increases iron-mediated energy production to promote multiple myeloma cell proliferation
por: Chen, Ying, et al.
Publicado: (2022)

Intratumor Heterogeneity of MIF Expression Correlates With Extramedullary Involvement of Multiple Myeloma
por: Xu, Juan, et al.
Publicado: (2021)

CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma
por: Gu, Chunyan, et al.
Publicado: (2021)

Prognostic Significance of the Stage at Which an MRD-Negative Status Is Achieved for Patients With Multiple Myeloma Who Received ASCT
por: Sun, Qian, et al.
Publicado: (2022)

Circulating Plasma Cells as a Biomarker to Predict Newly Diagnosed Multiple Myeloma Prognosis: Developing Nomogram Prognostic Models
por: Cheng, Qianwen, et al.
Publicado: (2021)

Inhibition of VCP modulates NF-κB signaling pathway to suppress multiple myeloma cell proliferation and osteoclast differentiation
por: Wei, Rongfang, et al.
Publicado: (2023)

Editorial: Molecular Mechanisms of Multiple Myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

LTe2 induces cell apoptosis in multiple myeloma by suppressing AKT phosphorylation at Thr308 and Ser473
por: Zhang, Yuanjiao, et al.
Publicado: (2023)

PIWIL1 Drives Chemoresistance in Multiple Myeloma by Modulating Mitophagy and the Myeloma Stem Cell Population
por: Wang, Yajun, et al.
Publicado: (2022)

Antidepressant Effects of (+)-MK-801 and (-)-MK-801 in the Social Defeat Stress Model
por: Yang, Bangkun, et al.
Publicado: (2016)

Serum Abnormal Metabolites for Evaluating Therapeutic Response and Prognosis of Patients With Multiple Myeloma
por: Wei, Yujun, et al.
Publicado: (2022)

Integrative Analysis of a Pyroptosis-Related Signature of Clinical and Biological Value in Multiple Myeloma
por: Wang, Huizhong, et al.
Publicado: (2022)

Dual Targeting of Multiple Myeloma Stem Cells and Myeloid-Derived Suppressor Cells for Treatment of Chemotherapy-Resistant Multiple Myeloma
por: Uckun, Fatih M.
Publicado: (2021)

G6PD promotes cell proliferation and dexamethasone resistance in multiple myeloma via increasing anti-oxidant production and activating Wnt/β-catenin pathway
por: Li, Rui, et al.
Publicado: (2022)

A novel ferroptosis-related gene signature for predicting prognosis in multiple myeloma
por: Gao, Dandan, et al.
Publicado: (2023)

Shikonin induces ferroptosis in multiple myeloma via GOT1-mediated ferritinophagy
por: Li, Wenxia, et al.
Publicado: (2022)

MK2206 enhances the cytocidal effects of bufalin in multiple myeloma by inhibiting the AKT/mTOR pathway
por: Xiang, Ru-Fang, et al.
Publicado: (2017)

An Uncommon Cause of Acute Encephalopathy in Multiple Myeloma
por: Al Zeyoudi, Jawaher, et al.
Publicado: (2021)

PET/CT in Multiple Myeloma: Beyond FDG
por: Matteucci, Federica, et al.
Publicado: (2021)

Editorial: T-cell directed therapies in multiple myeloma
por: Richter, Joshua, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_829s643vnnbf59h17voc8quf1d